Research chemicalResearch chemicalInvestigational anorecticTriple reuptake inhibitor

Tesofensine

Also known as NS2330 · TE

Written by enwyReviewed 5 Aug 20261 sources0 comments

An investigational triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) originally studied for Parkinson's and Alzheimer's disease, then repurposed for obesity after weight loss was noticed in trials. Phase II data showed strong weight loss, but it is not approved anywhere and remains investigational with dose-dependent cardiovascular and mood concerns.

01 Overview

Tesofensine (NS2330) inhibits reuptake of serotonin, noradrenaline and dopamine, an unusually broad monoaminergic profile that suppresses appetite. Its earlier neurodegenerative-disease trials failed, but a Phase II obesity trial (TIPO-1) reported placebo-subtracted weight loss of around 9-10% at the top dose over 24 weeks — larger than approved oral drugs of its era.

Despite that efficacy it has not reached the market; higher doses raised heart rate and blood pressure and produced mood/psychiatric and sleep effects, and later development stalled. It appears in the grey/research-chemical market, where quality and safety are unverified.

02 Mechanism

Triple reuptake inhibitor of serotonin, noradrenaline and dopamine, enhancing central monoaminergic tone to suppress appetite and increase satiety.

03 Dosing

Tier	Dose	Route	Notes
Trial dose (TIPO-1)	0.25–1 mg/day	Oral	0.25-1.0 mg once daily in Phase II; not an approved regimen.

04 Effects

Effect	Magnitude	Evidence
Weight lossLarge placebo-subtracted weight loss in TIPO-1, though from a single mid-stage trial.	~9-10% at top dose (Phase II)	Clinical
Appetite suppressionStrong reduction in hunger via broad monoaminergic action.	marked	Clinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Increased heart rate and blood pressureDose-related rise in pulse and blood pressure, a key barrier to development.	Moderate	Dose-dependent	Clinical
Mood, sleep and GI effectsInsomnia, mood changes, nausea, dry mouth and constipation.	Moderate	Common	Clinical

06 Legal status

United States

Investigational, not approved

No approved marketing; not an approved medicine. · as of Jan 2026

Investigational, not approved

Never approved. · as of Jan 2026

07 References

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients (TIPO-1)The Lancet, 2008 (Astrup et al.)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.